Pharmacotherapy of cryptococcosis

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 15, 2009, Pages 2433-2443

  Ritter, Michele ^a   Goldman, David L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antifungal; Cryptococcosis; Meningitis; Pneumonia

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; DIPHENHYDRAMINE; FLUCONAZOLE; FLUCYTOSINE; HYDROCORTISONE; ITRACONAZOLE; PARACETAMOL; PETHIDINE; POSACONAZOLE; TRIAZOLE; VORICONAZOLE;

ACUTE KIDNEY FAILURE; AGRANULOCYTOSIS; ANEMIA; ANTIFUNGAL ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CLINICAL FEATURE; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; FEVER; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; KIDNEY FAILURE; LIVER TOXICITY; LUNG CRYPTOCOCCOSIS; LUNG DISEASE; MORTALITY; MYCOSIS; NAUSEA; NEUTROPENIA; NORMOCHROMIC NORMOCYTIC ANEMIA; PERIPHERAL EDEMA; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIFUNGAL AGENTS; CLINICAL TRIALS AS TOPIC; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HUMANS; IMMUNOCOMPROMISED HOST; OPPORTUNISTIC INFECTIONS;

EID: 70349378486     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903200642     Document Type: Review

References (113)

1. Mirza SA, Phelan M, Rimland D, etal. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003;36:789-94 • Eight-year survey of two metropolitan areas in the USA reveals an approximately 10-fold decrease in the annual incidence of cryptococcosis from 1992 to 2000.
2. van Elden LJ, Walenkamp AM, Lipovsky MM, et al. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. AIDS 2000;14:2787-2788 (Pubitemid 32118732)
3. Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009;23:525-30 •• Study highlights the high burden of cryptococcosis globally and especially sub-Saharan Africa, where deaths due to cryptococcosis may be more common than tuberculosis.
4. Littman ML, Schneierson SS. Cryptococcus neoformans in pigeon excreta in New York City. Am J Hyg 1959;69:49-59
5. Emmons CW. Saprophytic sources of Cryptococcus neoformans associated with the pigeon (Columba livia). Am J Hyg 1955;62:227-232
6. Kwon-Chung KJ, Varma A. Do major species concepts support one, two or more species within Cryptococcus neoformans? FEMS Yeast Res 2006;6:574-587
7. Hoang LM, Maguire JA, Doyle P, et al. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J Med Microbiol 2004;53:935-940
8. Goldman DL, Khine H, Abadi J, et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 2001;107:E66
9. Perfect JR, Casadevall A. Human cryptococcosis. In: Perfect JR, Casadevall A, editors, Cryptococcus neoformans. Washington DC: ASM Press, 1998. p. 407-457
10. Arnaud L, Sene D, Costedoat-Chalumeau N, et al. Disseminated cryptococcal infection and anti-tumor necrosis factor-alpha treatment for refractory sarcoidosis: an expected association? J Rheumatol 2009;36:462-463
11. Tuxen AJ, Yong MK, Street AC, Dolianitis C. Disseminated cryptococcal infection in a patient with severe psoriasis treated with efalizumab, methotrexate and ciclosporin. Br J Dermatol 2007;157:1067-1068 (Pubitemid 47583519)
12. Bassetti M, Repetto E, Mikulska M, et al. Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature. J Chemother 2009;21:211-214
13. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001;33:690-9 • Multicenter reveals that the majority of HIV-negative patients with cryptococcosis have underlying conditions. Mortality associated with cryptococcosis was significant and specific risk factors (age > 60years, hematologic malignancy, organ failure) for death were identified.
14. Lortholary O, Poizat G, Zeller V, et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 2006;20:2183-91 • Multicenter, retrospective study conducted in France demonstrates a significant decrease in both long-term mortality and cryptococcosis relapse in association with HAART. (Pubitemid 44684709)
15. Kontoyiannis DP, Lewis RE, Alexander BD, et al. Calcineurin inhibitor agents interact synergistically with antifungal agents invitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother 2008;52:735-738
16. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992;15:1003-1018
17. Utz JP, Tynes BS, Shadomy HJ, et al. 5-Fluorocytosine in human cryptococcosis. Antimicrob Agents Chemother (Bethesda) 1968;8:344-346
18. Hsu SF, Burnette RR. The effect of amphotericin B on the K-channel activity of MDCK cells. Biochim Biophys Acta 1993;1152:189-191 (Pubitemid 23299051)
19. Sau K, Mambula SS, Latz E, etal. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem 2003;278:37561-37568 (Pubitemid 37175278)
20. Mozaffarian N, Berman JW, Casadevall A. Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrob Agents Chemother 1997;41:1825-1829 (Pubitemid 27339897)
21. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-693 (Pubitemid 32221925)
22. Sawaya BP, Weihprecht H, Campbell WR, et al. Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest 1991;87:2097-2107
23. Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005;40(Suppl 6):414-421
24. Aguado JM, Lumbreras C, Gonzalez-Vidal D. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain. Clin Microbiol Infect 2004;10:785-790 (Pubitemid 39276311)
25. Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003;25:1295-1320 (Pubitemid 36677281)
26. Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 1998;26:1362-1366 (Pubitemid 28270166)
27. Milefchik E, Leal MA, Haubrich R, et al. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 2008;46:393-395 (Pubitemid 351552497)
28. Chotmongkol V, Sukeepaisarncharoen W, Thavornpitak Y. Comparison of amphotericin B, flucytosine and itraconazole with amphotericin B and flucytosine in the treatment of cryptococcal meningitis in AIDS. J Med Assoc Thai 1997;80:416-425 (Pubitemid 27430694)
29. Parisi A, Malfitano A, Bruno R, et al. Efficacy of a short-term amphotericin B + flucytosine combination therapy followed by itraconazole monotherapy in acute and chronic AIDS-associated cryptococcosis. Mycoses 1997;40:203-207 (Pubitemid 28018493)
30. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000;30:710-718 (Pubitemid 30736975)
31. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-1131
32. Alexander BD, Perfect JR, Daly JS, et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 2008;86:791-796
33. Bandettini R, Castagnola E, Calvillo M, et al. Voriconazole for cryptococcal meningitis in children with leukemia or receiving allogeneic hemopoietic stem cell transplant. J Chemother 2009;21:108-109
34. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997;41:2333-2338
35. Feldmesser M, Kress Y, Mednick A, Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 2000;182:1791-1795 (Pubitemid 30951807)
36. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007;4:e21 • Prospective, multicenter study that found that disseminated disease at presentation, high serum antigen and lack of 5-FC therapy correlated with microbiologic failure at 2weeks. (Pubitemid 46354443)
37. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992;326:83-9 •• One of earliest studies to demonstrate the potential usefulness of fluconazole for the initial treatment of CME. Patients treated with fluconazole had higher mortality at 2weeks. Time to sterilization of CSF with fluconazole was also more prolonged, though this difference was not statistically significant.
38. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med 1974;80:176-181
39. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979;301:126-31 • A study of 50 non-AIDS patients in which combination therapy produced fewer treatment failures, relapses and more rapid CSF sterilization when compared with AmB alone.
40. Shadomy S, Wagner G, Espinel-Ingroff E, Davis BA. Invitro studies with combinations of 5-fluorocytosine and amphotericin B. Antimicrob Agents Chemother 1975;8:117-121
41. Chen HH, Liushih RN, Hsieh WC. Combined invitro activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans and Candida albicans. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1982;15:106-112
42. Schwarz P, Dromer F, Lortholary O, Dannaoui E. Invitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother 2003;47:3361-3364 (Pubitemid 37229607)
43. Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987;317:334-341 (Pubitemid 17118707)
44. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337:15-21 •• Study demonstrates the utility of a staged approach to CME therapy with amphotericin + flucytosine in the initial treatment, followed by fluconazole or itraconazole.
45. Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE 2008;3:e2870 • Observational study supports superiority of AmB+5-FC compared to other regimens. High serum antigen titers and mengoencephalititis at presentation also associated with treatment failure.
46. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004;363:1764-7 •• Comparison of AmB, Amb+5-FC. AmB +Fluconazole and AmB+ 5-FC +Fluconazole for the treatment of CME. AmB+5FC was found to produce most rapid CSF clearance. High baseline CSF fungal burden found to be a bad prognostic indicator. (Pubitemid 38698379)
47. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008;47:123-130 (Pubitemid 351920599)
48. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 1990;113:183-187 (Pubitemid 20242293)
49. Bicanic T, Harrison T, Niepieklo A, et al. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006;43:1069-1073 (Pubitemid 44631110)
50. Schaars CF, Meintjes GA, Morroni C, et al. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infect Dis 2006;6:118 (Pubitemid 46277110)
51. Longley N, Muzoora C, Taseera K, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008;47:1556-1561
52. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19:741-745 (Pubitemid 24301152)
53. Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1991;324:580-584
54. Singh N, Lortholary O, Alexander BD, et al. Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation 2005;80:1033-1039 (Pubitemid 41611924)
55. Mussini C, Pezzotti P, Miro JM, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004;38:565-571 (Pubitemid 38250968)
56. Aberg JA, Price RW, Heeren DM, Bredt B. A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J Infect Dis 2002;185:1179-1182 (Pubitemid 34297778)
57. Martinez E, Garcia-Viejo MA, Marcos MA, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS 2000;14:2615-2617 (Pubitemid 30840058)
58. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000;30:47-54 (Pubitemid 30067061)
59. Shoham S, Cover C, Donegan N, et al. Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2005;40:477-9 •• Study observed that departures from IDSA clinical guidelines for the treatment of CME were common and that failure to address increased ICP was associated with neurologic injury. (Pubitemid 40216519)
60. Newton PN, Thai LH, Tip NQ, etal. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002;35:769-772
61. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007;45:76-80 (Pubitemid 46984619)
62. Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 2002;35:e128-33
63. Woods ML, MacGinley R, Eisen DP, Allworth AM. HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS 1998;12:1491-1494 (Pubitemid 28369649)
64. Campbell GD. Primary pulmonary cryptococcosis. Am Rev Respir Dis 1966;94:236-243
65. Henson DJ, Hill AR. Cryptococcal pneumonia: a fulminant presentation. Am J Med Sci 1984;288:221-222
66. Duperval R, Hermans PE, Brewer NS, Roberts GD. Cryptococcosis, with emphasis on the significance of isolation of Cryptococcus neoformans from the respiratory tract. Chest 1977;72:13-19 (Pubitemid 8144198)
67. Murray RJ, Becker P, Furth P, Criner GJ. Recovery from cryptococcemia and the adult respiratory distress syndrome in the acquired immunodeficiency syndrome. Chest 1988;93:1304-1306 (Pubitemid 18154510)
68. Woodring JH, Ciporkin G, Lee C, et al. Pulmonary cryptococcosis. Semin Roentgenol 1996;31:67-75
69. Himmel JE, Stark P. Cryptococcal pneumonia in an immunocompetent host: radiographic findings. Semin Respir Infect 2003;18:129-131 (Pubitemid 36718485)
70. Aberg JA, Mundy LM, Powderly WG. Pulmonary cryptococcosis in patients without HIV infection. Chest 1999;115:734-740 (Pubitemid 29129954)
71. Baddley JW, Perfect JR, Oster RA, et al. Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis 2008;27:937-43 • A retrospective review of HIV-negative patients with pulmonary cryptococcosis, involving 15 medical centers. Cirrhosis, headache, weight loss, fever, altered mental status and high-dose corticosteroids were associated with disseminated disease. A negative serum antigen was much more common with isolated pulmonary disease.
72. Wasser L, Talavera W. Pulmonary cryptococcosis in AIDS. Chest 1987;92:692-695
73. Clark RA, Greer DL, Valainis GT, Hyslop NE. Cryptococcus neoformans pulmonary infection in HIV-1-infected patients. J Acquir Immune Defic Syndr 1990;3:480-484 (Pubitemid 20251502)
74. Meyohas MC, Roux P, Bollens D, et al. Pulmonary cryptococcosis: localized and disseminated infections in 27patients with AIDS. Clin Infect Dis 1995;21:628-633
75. Cameron ML, Bartlett JA, Gallis HA, Waskin HA. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis 1991;13:64-67
76. Smith FS, Gibson P, Nicholls TT, Simpson JA. Pulmonary resection for localized lesions of cryptococcosis (torulosis): a review of eight cases. Thorax 1976;31:121-126
77. Perkins W. Pulmonary cryptococcosis: report on the treatment of nine cases. Dis Chest 1969;56:389-394
78. Liu M, Jiang GN. Surgical treatment of pulmonary cryptococcosis. Zhonghua Jie He He Hu Xi Za Zhi 2006;29:307-309
79. Schupbach CW, Wheeler CE Jr, Briggaman RA, etal. Cutaneous manifestations of disseminated cryptococcosis. Arch Dermatol 1976;112:1734-1740
80. Gauder JP. Cryptococcal cellulitis. JAMA 1977;237:672-673
81. Dharmshale SN, Patil SA, Gohil A, et al. Disseminated crytococcosis with extensive cutaneous involvement in AIDS. Indian J Med Microbiol 2006;24:228-230 (Pubitemid 44315661)
82. Vogelaers D, Petrovic M, Deroo M, etal. A case of primary cutaneous cryptococcosis. Eur J Clin Microbiol Infect Dis 1997;16:150-152 (Pubitemid 27135966)
83. Larsen RA, Bozzette S, McCutchan JA, et al. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California Collaborative Treatment Group. Ann Intern Med 1989;111:125-8 • Study demonstrates the presence of C. neoformans in the urine and prostatic secretions of patients following treatment for CME, and suggests that the prostate may serve as a sanctuary site for C. neoformans.
84. Dromer F, Charreire J. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J Infect Dis 1991;163:1114-1120
85. Mukherjee S, Lee S, Mukherjee J, et al. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun 1994;62:1079-1088 (Pubitemid 24065599)
86. Sanford JE, Lupan DM, Schlageter AM, Kozel TR. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun 1990;58:1919-1923
87. Feldmesser M, Casadevall A, Kress Y, et al. Eosinophil-Cryptococcus neoformans interactions invivo and invitro. Infect Immun 1997;65:1899-1907 (Pubitemid 27193617)
88. Lee SC, Kress Y, Dickson DW, Casadevall A. Human microglia mediate anti-Cryptococcus neoformans activity in the presence of specific antibody. J Neuroimmunol 1995;62:43-52
89. Monari C, Casadevall A, Retini C, et al. Antibody to capsular polysaccharide enhances the function of neutrophils from patients with AIDS against Cryptococcus neoformans. AIDS 1999;13:653-660 (Pubitemid 29286699)
90. Feldmesser M, Casadevall A. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J Immunol 1997;158:790-799 (Pubitemid 127492656)
91. Mukherjee J, Pirofski LA, Scharff MD, Casadevall A. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci USA 1993;90:3636-3640 (Pubitemid 23111422)
92. Dadachova E, Bryan RA, Apostolidis C, et al. Interaction of radiolabeled antibodies with fungal cells and components of the immune system invitro and during radioimmunotherapy for experimental fungal infection. J Infect Dis 2006;193:1427-1436 (Pubitemid 43673391)
93. Larsen RA, Pappas PG, Perfect J, et al. PhaseI evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 2005;49:952-8 • Study examines the effects of capsular mAb on the clearance of cryptococcal polysaccharide in patients that had been treated for CME. High doses of mAb produced more rapid polysaccharide clearance, but were also associated with increased HIV replication. (Pubitemid 40327709)
94. Mody CH, Tyler CL, Sitrin RG, et al. Interferon-gamma activates rat alveolar macrophages for anticryptococcal activity. Am J Respir Cell Mol Biol 1991;5:19-26
95. Perfect JR, Granger DL, Durack DT. Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. J Infect Dis 1987;156:316-323
96. Herrmann JL, Dubois N, Fourgeaud M, et al. Synergic inhibitory activity of amphotericin-B and gamma interferon against intracellular Cryptococcus neoformans in murine macrophages. J Antimicrob Chemother 1994;34:1051-1058
97. Lovchik JA, Lyons CR, Lipscomb MF. A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am J Respir Cell Mol Biol 1995;13:116-124
98. Tohyama M, Kawakami K, Futenma M, Saito A. Enhancing effect of oxygen radical scavengers on murine macrophage anticryptococcal activity through production of nitric oxide. Clin Exp Immunol 1996;103:436-441 (Pubitemid 26092005)
99. Bava AJ, Afeltra J, Negroni R, Diez RA. Interferon gamma increases survival in murine experimental cryptococcosis. Rev Inst Med Trop Sao Paulo 1995;37:391-396 (Pubitemid 26027659)
100. Clemons KV, Lutz JE, Stevens DA. Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice. Antimicrob Agents Chemother 2001;45:686-689
101. Joly V, Saint-Julien L, Carbon C, Yeni P. Invivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994;170:1331-1334 (Pubitemid 24328650)
102. Chen GH, McDonald RA, Wells JC, et al. The gamma interferon receptor is required for the protective pulmonary inflammatory response to Cryptococcus neoformans. Infect Immun 2005;73:1788-1796
103. Kawakami K, Tohyama M, Teruya K, et al. Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol Med Microbiol 1996;13:123-130 (Pubitemid 26122873)
104. Wormley FL Jr, Perfect JR, Steele C, Cox GM. Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect Immun 2007;75:1453-1462 (Pubitemid 46385839)
105. Siddiqui AA, Brouwer AE, Wuthiekanun V, et al. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol 2005;174:1746-1750
106. Netea MG, Brouwer AE, Hoogendoorn EH, et al. Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon-gamma therapy. Clin Infect Dis 2004;39:e83-7
107. Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004;189:2185-91 • Phase II study found a trend towards more rapid CSF sterilization in association with adjunctive IFN-γ therapy. (Pubitemid 38757190)
108. Datta K, Lees A, Pirofski LA. Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan. Clin Vaccine Immunol 2008;15:1176-1187
109. Nussbaum G, Anandasabapathy S, Mukherjee J, etal. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice. Infect Immun 1999;67:4469-4476
110. Mansour MK, Yauch LE, Rottman JB, Levitz SM. Protective efficacy of antigenic fractions in mouse models of cryptococcosis. Infect Immun 2004;72:1746-1754
111. Harrison TS. The burden of HIV-associated cryptococcal disease. AIDS 2009;23:531-532
112. Jarvis JN, Lawn SD, Vogt M, et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009;48:856-62 •• Demonstrates potential utility of screening for cryptococcal serum antigenemia for AIDS patients from South Africa with CD4 cell counts < 100/μl. Seven per cent of stored serum from an antiretroviral therapy study were found to be antigen positive. Antigenemia was 100% sensitive for predicting development of cryptococcal meningitis during the first year of therapy, and in multivariate analysis, it was an independent predictor of mortality.
113. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007;12:929-935 (Pubitemid 47245826)